Maïa Chanrion

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening

Eric T. Sawey, Maïa Chanrion, Chunlin Cai et al. · Cancer Cell · 2011 · 433 citations · Full text

Medicine, Molecular Biology, Oncology +16

CIP2A Is Associated with Human Breast Cancer Aggressivity

Christophé Côme, Anni Laine, Maïa Chanrion et al. · Clinical Cancer Research · 2009 · 226 citations · Full text

Life Sciences, Molecular Biology, Oncology +12

A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer

Maïa Chanrion, Vincent Nègre, Hélène Fontaine et al. · Clinical Cancer Research · 2008 · 202 citations · Full text

Medicine, Cancer Biology, Oncology +17

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

Delphine Mérino, James R. Whittle, François Vaillant et al. · Science Translational Medicine · 2017 · 192 citations

Medicine, Oncology, Pharmacology +14